

Durham Research Online

Deposited in DRO:

05 December 2019

Version of attached file:

Published Version

Peer-review status of attached file:

Peer-reviewed

Citation for published item:

Mbekeani, A.J. and Jones, R.S. and Bassas Llorens, M. and Elliot, J. and Regnault, C. and Barrett, M.P. and Steele, J. and Kebede, B. and Wrigley, S.K. and Evans, L. and Denny, P.W. (2019) 'Mining for natural product antileishmanials in a fungal extract library.', *International journal for parasitology : drugs and drug resistance.*, 11 . pp. 118-128.

Further information on publisher's website:

<https://doi.org/10.1016/j.ijpddr.2019.05.003>

Publisher's copyright statement:

© 2019 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Additional information:


Use policy

The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-profit purposes provided that:

- a full bibliographic reference is made to the original source
- a [link](#) is made to the metadata record in DRO
- the full-text is not changed in any way

The full-text must not be sold in any format or medium without the formal permission of the copyright holders.

Please consult the [full DRO policy](#) for further details.



Mining for natural product antileishmanials in a fungal extract library

A.J. Mbekeani^a, R.S. Jones^a, M. Bassas Llorens^a, J. Elliot^a, C. Regnault^b, M.P. Barrett^{b,c}, J. Steele^d, B. Kebede^d, S.K. Wrigley^d, L. Evans^d, P.W. Denny^{a,*}

^a Department of Biosciences and Centre for Global Infectious Diseases, Durham University, Stockton Road, Durham, DH1 3LE, UK

^b Glasgow Polyomics, College of Medical, Veterinary & Life Sciences, University of Glasgow, Garscube Estate, Bearsden, Glasgow, G61 1QH, UK

^c Wellcome Centre for Integrative Parasitology, Institute of Infection, Immunity and Inflammation, University of Glasgow, University Place, Glasgow, G12 8TA, UK

^d Hypha Discovery Ltd., 957 Buckingham Avenue, Slough, SL1 4NL, UK

ARTICLE INFO

Keywords:

Cutaneous leishmaniasis
Leishmania mexicana
Natural product
Screening
Fractionation
Metabolomics

ABSTRACT

Leishmaniasis is a Neglected Tropical Disease caused by the insect-vector borne protozoan parasite, *Leishmania* species. Infection affects millions of the World's poorest, however vaccines are absent and drug therapy limited. Recently, public-private partnerships have developed to identify new modes of controlling leishmaniasis. Most of these collaborative efforts have relied upon the small molecule synthetic compound libraries held by industry, but the number of New Chemical Entities (NCE) identified and entering development as antileishmanials has been very low. In light of this, here we describe a public-private effort to identify natural products with activity against *Leishmania mexicana*, a causative agent of cutaneous leishmaniasis (CL). Utilising Hypha Discovery's fungal extract library which is rich in small molecule (< 500 molecular weight) secondary metabolites, we undertook an iterative phenotypic screening and fractionation approach to identify potent and selective antileishmanial hits. This led to the identification of a novel oxidised bisabolane sesquiterpene which demonstrated activity in an infected cell model and was shown to disrupt multiple processes using a metabolomic approach. In addition, and importantly, this study also sets a precedent for new approaches for CL drug discovery.

1. Introduction

The Neglected Tropical Disease (NTD) leishmaniasis is endemic in over 90 countries worldwide, affecting approximately 12 million people per year with 350 million people living at risk of disease. The causative agent, *Leishmania* species, are sand fly borne kinetoplastid protozoan parasites (Stuart et al., 2008) and infection leads to a wide spectrum of clinical manifestations in endemic areas, from self-healing but scarring cutaneous leishmaniasis (CL) to fatal visceral disease (VL). Amongst other factors, this diversity of disease is dependent on the parasite species, host immunity and genetic background (Reithinger et al., 2007). Largely due to elimination efforts in south Asia, the global burden of VL has decreased substantially in the past decade. However, due to forced migration, the cases of CL have substantially increased in the same period (0.7–1 million per year) (Burza et al., 2018).

A vaccine to prevent leishmaniasis is not available and treatment relies entirely on a limited arsenal of chemotherapeutics. Recent years have seen the emergence of public-private partnerships which have used industrial scale (> 1,000,000) compound libraries to screen for antileishmanials either phenotypically (Khare et al., 2016; Pena et al., 2015) or target-based (Norcliffe et al., 2018). However, all the major

initiatives have focused on VL leaving CL, the most common form of leishmaniasis, as a neglected NTD. Current treatment of CL largely relies on the pentavalent antimonials such as sodium stibogluconate (Pentostam) and meglumine antimoniate (Glucantime) (Croft and Coombs, 2003; Kedzierski et al., 2009). Both Pentostam and Glucantime have been in clinical use for over 70 years despite their associated problems, which include severe side-effects such as cardiotoxicity (Chappuis et al., 2007) and the fact that they require parenteral administration (Demicheli et al., 2004). In addition, the use of pentavalent antimonials in the treatment of leishmaniasis is under threat from the emergence of drug resistance (Croft et al., 2006). Amphotericin B (Fungizone) (Thakur et al., 1999) and diamidine pentamidine (Bray et al., 2003) are employed as second-line drugs in the treatment of CL. Like the antimonials, they induce severe side-effects and parasite resistance, although not yet conclusively confirmed in the field, has been observed under laboratory conditions (Di Giorgio et al., 1999). Given the aforementioned issues with both the current first- and second-line drugs used to treat CL there is clearly a need to develop new and effective therapies for this disease.

Natural products have long formed the backbone of traditional therapies, including for leishmaniasis (Charlton et al., 2018; Cockram

* Corresponding author.

E-mail address: p.w.denny@durham.ac.uk (P.W. Denny).

<https://doi.org/10.1016/j.ijpddr.2019.05.003>

Received 11 February 2019; Received in revised form 1 May 2019; Accepted 20 May 2019

Available online 11 June 2019

2211-3207/ © 2019 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

and Smith, 2018). The active compounds of these medicines include vast numbers of alkaloids (Mishra et al., 2009), flavonoids (da Silva et al., 2012; Mittra et al., 2000), chalcones (Aponte et al., 2010; Boeck et al., 2006; Chen et al., 1994; de Mello et al., 2014) and terpenoids (Arruda et al., 2005; do Socorro et al., 2003). It should also be noted that the second-line CL drug amphotericin B is itself a natural product, originally isolated from *Streptomyces nodosus* as an antifungal in 1955 (Dutcher, 1968).

Given this history, it is logical to consider the natural world as a potential source of novel antileishmanials. Hypha Discovery's (<http://www.hyphadiscovery.co.uk>) large-scale extract (HDLX) library of 1–5 L volume fermentation extracts is derived from the company's unique collection of higher fungal strains, namely the mushroom-producing basidiomycetes and ascomycetes, which are underexplored in the field of antiprotozoal drug discovery. The producing strains included in the library are regarded as being biosynthetically talented since they had all demonstrated production of bioactivity in various whole cell-based assays against microbial pathogens and/or human tumour cell lines. In this paper we describe a collaborative effort to exploit this resource for the discovery of novel antileishmanials. Utilising an iterative process of screening against the CL pathogen *Leishmania mexicana* and mammalian cells, followed by fractionation and scale up of identified parasite selective hits, following dereplication we identified a known antileishmanial class and, more importantly, a novel oxidised bisabolane sesquiterpene which demonstrated activity in an infected cell model. The mode of action of this latter hit was investigated using a metabolomics approach.

2. Materials and Methods

2.1. HDLX library generation and format

Scale-up fermentations of fungi selected for inclusion in the HDLX library were obtained in multiple shake flasks (each 250 mL Erlenmeyer flask containing 100 mL Leatham's medium, contents per litre of water: D-Glucose (25.00 g), L(+)-glutamic acid monosodium salt monohydrate (3.20 g), KH_2PO_4 (2.00 g), $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ (2.00 g), mineral solution (10 mL), trace element solution (1.0 mL), vitamin solution (1.0 mL) and 1% aqueous salicylic acid (0.10 mL)) to a total volume of 1–5 L. The fermentations were harvested after the same period of time that yielded the original activity of interest and this could vary from as little as three to as many as one hundred days. Aqueous broth actives were harvested by various methods depending on the polarities of the components of interest including extraction with ethyl acetate or capture using Diaion HP20 resin and elution with methanol/acetonitrile. Biomass actives were extracted using methanol-acetone (1:1). The extracts were concentrated to dryness for storage. The extracts were weighed and portions stored in 96-well blocks as 10 mg/mL solutions in DMSO. All of the purification and bioactive compound identification work described within this manuscript was conducted on the initially available HDLX library materials without the need for re-fermentation of the producing fungal strains, as per the original intention of the library. For subsequent analyses, further HD871-1 material was obtained by re-fermentation.

2.2. Cell culture

Leishmania mexicana (MNYC/BZ/62/M379) were maintained at 26 °C in Schneider's Drosophila media (Sigma Aldrich) supplemented with heat inactivated foetal bovine sera (HIFBS; 15% for promastigotes, and 20% for amastigotes; Biosera). Promastigotes were transformed into axenic amastigotes by a pH and temperature shift as previously described (Bates, 1994). *Ceropithecus aethiops* kidney (Vero) cells (ATCC CCL-81) and *Mus musculus* leukaemia virus transformed macrophage (RAW267.4) cells (ATCC TIB-71) were cultured in Dulbecco's Modified Eagles Medium (DMEM; Fisher Scientific) supplemented with 10%

HIFBS (Biosera). Cells were counted using a Neubauer Improved Haemocytometer.

2.3. Screening against axenic amastigote forms

Cytotoxicity analyses were performed in 96-well plates (Nunc) using alamarBlue® (Life Technologies) with some modifications to the published, optimized protocol (Chadbourne et al., 2011). Briefly, in initial screens, extracts or isolated compounds were incubated with 100 μL axenic amastigote *L. mexicana* at $5 \times 10^5 \text{ mL}^{-1}$ for 24 h at 33 °C before the addition of 10 μL of alamarBlue® and incubation for a further for 24 h at the same temperature, all in Parafilm (Fisher Scientific) sealed plates. Counter screening was performed against Vero cells, with plates seeded with 5×10^3 cells per well. Following overnight incubation at 37 °C, 5% CO_2 , cells were incubated with extracts or isolated compounds in 100 μL of media for 24 h in the same conditions and then for a further 4 h following the addition of 10 μL of alamarBlue®. Subsequently cell viability was assessed using a fluorescent plate reader (Biotek; 560EX nm/600 EM nm), with amphotericin B as positive (10 μM) and DMSO as negative controls.

Initial screening of the HDLX library (313 extracts) was carried out using a dose response approach, in duplicate against both axenic amastigote *L. mexicana* and mammalian Vero cells. The Selectivity Index (SI) was calculated from these data ($\text{EC}_{50} \text{ Vero} / \text{EC}_{50} \text{ L. mexicana}$). Subsequent fractions were screened at single concentrations in duplicate against the parasite. Determination of the EC_{50} of the identified novel antileishmanial against axenic amastigote *L. mexicana* was carried out using the same assay in triplicate on three separate occasions to ensure a robust data set was collected.

2.4. Screening against infected macrophages

Efficacy against *L. mexicana* infected macrophages was tested as previously described (Bolt et al., 2016; Eggimann et al., 2015). The RAW264.7 cells were seeded in 96-well plates at $2.5 \times 10^5 \text{ mL}^{-1}$ (200 μL /well) in DMEM (10% HIFBS) and incubated for 24 h at 37 °C, 5% CO_2 . Following washing with DMEM (2% HIFBS), *L. mexicana* axenic amastigotes (or not for RAW264.7 cytotoxicity) were added at $25 \times 10^5 \text{ mL}^{-1}$ (200 μL /well) in DMEM (2% HIFBS) and plate incubated for 24 h at 37 °C, 5% CO_2 . Subsequently, the infected RAW264.7 cells were washed carefully $5 \times$ with DMEM (2% HIFBS) before adding 100 μL /well of fresh DMEM (2% HIFBS) to each well. Isolated compounds and control (10 μM amphotericin B and DMSO vehicle) were added at the required concentrations before a further incubation for 24 h at 37 °C, 5% CO_2 . Finally, the infected macrophages cells were washed $3 \times$ with Schneider's Insect medium (serum-free) and then lysed with 20 μL /well of SDS (0.05%, v/v in Schneider's) for 30 s before the addition of 180 μL /well of Schneider's Insect medium (pH7, 15% HIFBS). Plates were Parafilm sealed and incubated for 48 h at 26 °C. Subsequently, 10 μL of alamarBlue® was added to each well before a 4 h incubation at 26 °C prior to assessing parasite viability using a fluorescent plate reader (Biotek; 560EX nm/ 600 EM nm). All of the experiments described above were carried out on a three separate occasions in triplicate to ensure a robust data set was collected. The Selectivity Index (SI) was calculated from these data ($\text{EC}_{50} \text{ RAW267.4} / \text{EC}_{50} \text{ intracellular L. mexicana}$).

2.5. Assay-guided purification

Preliminary small-scale activity-guided purification studies on hits from 12 organisms that showed promising antiparasitic activity profiles ($\text{EC}_{50} < 1 \text{ mg/mL}$; therapeutic index > 100) were conducted using semi-preparative HPLC approaches as follows: extract aliquots (0.9 mL) were chromatographed by reversed phase HPLC on an Xbridge Prep Phenyl 5 μm OBD column (19 mm \times 100 mm) with a guard column (19 mm \times 10 mm), using gradient elution of 10–100% acetonitrile in

water in the presence of 0.1% formic acid over 8 min, held at 100% acetonitrile for 3 min before returning to starting conditions over 1 min at a flow rate of 17 mL/min. 24 fractions were collected for each fractionation and concentrated to dryness in a Genevac HT12 centrifugal evaporator. The resulting dried fractions were re-dissolved in DMSO-MeOH (3:1, 0.45 mL) and aliquots (25 µL) transferred to 96 well microtiter plates, lyophilised for shipping.

Analysis of active fractions by HPLC-mass spectrometry employing an orthogonal reversed phase HPLC-MS method was conducted on a SymmetryShield RP8 column (3.5 µm; 4.6 mm × 75 mm) eluted with a linear gradient of 10–95% MeCN in water, containing 10 mM ammonium formate + 0.1% formic acid, at a flow rate of 1 mL/min, held at 95% MeCN for 1.0 min before returning to initial conditions over 0.5 min; total run time 12 min. UV–visible spectra were acquired using a Waters 2996 photodiode array detector and positive and negative ion electrospray mass spectra were acquired using a Waters Acquity SQ detector. Putative molecular weights, UV–Visible maxima and producing organism taxonomic data were used to search two natural products databases to identify known compounds, namely Antibase and the Chapman and Hall Dictionary of Natural Products.

Specific chromatographic methods were then developed for the most promising active primary fractions to separate and resolve their constituent components / HPLC peaks using a reversed phase column chemistry orthogonal to that used for the primary fractionation step (usually SymmetryShield RP8). The primary fraction was then fractionated on the semi-preparative scale and individual HPLC peaks collected into secondary fractions that were concentrated to dryness, re-dissolved and shipped for assay as described above.

2.6. Scale-up purification and structure elucidation

The target extracts were purified by preparative HPLC methods scaled-up from the purification methods developed from the small-scale assay guided purification investigations. HD871-1 was purified from the Diaion HP20 extract of a 5.0 L fermentation of *Marasmius* sp. HFN871. The extract was first chromatographed by preparative HPLC on a Waters Nova-Pak C18 column (40 × 100 mm with a 40 × 10 mm guard column) eluted with a gradient increasing linearly from 10 to 95% acetonitrile in water containing 0.1% formic acid over a period of 8 min at a flow rate of 50 mL/min. HPLC was used to check for the presence of the target metabolite with MH⁺ at m/z 263 and this was present in fractions eluting between 4.5 and 5.5 min. These were combined and further purified by semi-preparative HPLC on a Waters Atlantis T3 ODS column (10 × 250 mm) eluted isocratically with 45% aqueous acetonitrile containing 0.1% formic acid at a flow rate of 4.6 mL/min. HPLC-MS analysis showed that the compound of interest was present in fractions eluting from 8 to 9 min. A final purification step was achieved by semi-preparative HPLC on a Waters X-Select C18 column (19 × 100 mm with a 19 × 10 mm guard column) eluted with a linear gradient increasing from 25 to 30% aqueous acetonitrile containing 0.1% formic acid over a period of 14 min at a flow rate of 20 mL/min. The peak eluting at 10 min was collected and concentrated to dryness to yield pure HD871-1 (6.9 mg) as a colourless residue. ¹H and ¹³C NMR spectra were acquired at 500 MHz and 125 MHz, respectively, at 298 K in DMSO-d₆, on a Bruker AVANCE III 500 MHz NMR spectrometer at the University of Surrey, Guildford, UK. Datasets for structure elucidation included COSY, HSQC, HMBC and NOESY spectra, which were interpreted at Hypha Discovery using Mestrenova software. High resolution mass spectrometry was conducted on a Bruker micrOTOF-Q instrument.

2.7. Metabolite extraction

The optimal concentration of HD871-1 for this experiment was established by estimation of the half time of *L. mexicana* axenic amastigotes to death at 4 concentrations (1.25, 2.5, 5 and 10 µM) by

microscopic observation at 12, 24, 36 and 48 h. Subsequently the amastigotes, seeded at 1 × 10⁷ parasites/mL, were exposed to 10 µM HD871-1, or a vehicle (DMSO) control, for 36 h at 32 °C. Metabolites were then extracted and analysed as follows:

For LC-MS metabolomic analyses, sample extraction was performed as described (Creek et al., 2011; Kovářová et al., 2018). In summary, 10⁸ cells were rapidly cooled in a dry ice/ethanol bath to 4 °C, centrifuged, washed with 1 × PBS, and resuspended in 200 µL extraction solvent (chloroform:methanol:water, 1:3:1 vol ratio). Samples were centrifuged at 16,000 g (4 °C for 10 min) after shaking for 1 h at 4 °C. The supernatant was stored under argon at –80 °C until running on the mass spectrometer. Samples were first separated using HPLC with a 150 × 4.6 mm ZIC-pHILIC (Merck) column on UltiMate 3000 RSLC (Thermo Scientific). Mass detection used an Orbitrap Q-Exactive mass spectrometer (Thermo Fisher) at Glasgow Polyomics, using positive and negative polarity switching mode, with a 10 µL injection volume and flow rate of 300 µL/min. 249 authentic standards were included to assist compound identification. Data were processed and analysed using mzMatch (Scheltema et al., 2011) and IDEOM software (Creek et al., 2012). All the MS analyses were performed in at least triplicate. The Comparison page of the IDEOM file is included as supplementary material (Supplementary Table 1). This contains information on those masses detected as likely metabolites through the software processing. Exact mass is measured and this is converted, where possible to a formula corresponding to that mass. Screening of a database of metabolites with that formula then yields a putative identity. Where an authentic standard has a matching mass and retention time this is taken as a likely hit. Other annotations are tentative (metabolomics standards initiative level 2, Sumner et al., 2007) with this data.

3. Results

3.1. Primary screening

Utilising a 96-well protocol previously developed to identify antileishmanial compounds (Chadbourne et al., 2011) the HDLSX library (313 fungal extracts) was screened against mammalian stage *L. mexicana* axenic amastigotes in a dose response experiment. Extracts inhibiting with an EC₅₀ < 0.025 mg/mL (Effective Concentration eliciting 50% inhibition of proliferation) against the parasites were selected, and these 38 hits counter screened in the same manner against mammalian Vero cells. These hits represent complex mixtures with non-cytotoxic extracts possibly containing minor cytotoxic components, and conversely, non-active extracts may harbour minor antiparasitic components. However, to narrow down the extracts for further analyses, based on the screening data, potent hits with a selectivity index (SI) > 48 were initially selected. After subtracting those with known cytotoxicity and intellectual property issues we were left with 17 hits. Based on Hypha data, replicated extracts were removed leaving 12 hits (HDLSX-9, 14, 18, 21, 22, 33, 35, 67, 79, 127, 159, 171; Table 1), a hit rate of 3.8%.

3.2. Primary fractionation and secondary screening

As described in Materials and Methods primary fractionation was undertaken of the 12 hits, yielding 24 fractions per sample. 10 of the initial 12 hits had components demonstrating complete cytotoxic activity against axenic amastigotes at 1 mg/mL (fractions from HDLSX-9, 18, 21, 22, 35, 67, 79, 159, 171, 127; Fig. 1). Initial analyses by mass spectrometry indicated the complexity and, in some cases, content of the active fractions. For example, striatals (including striatal B) were present in HDLSX-21 (from HFN65 *Cyathus* cf. *crassimurus*). This was confirmed by chromatographic comparison with a pure sample of striatal B previously isolated from a *Cyathus* sp. fermentation at Hypha. The ¹H NMR spectrum of this material is shown in Supplementary Figure 1 and the signals observed are consistent with those previously

Table 1

The 38 potent hits ($EC_{50} < 0.025$ mg/ml against axenic amastigote *L. mexicana*) were counter screened against mammalian Vero cells. Those with a selectivity index (SI) > 48 were initially selected. Final selection (12 hits, Y in bold) was made after subtracting those with known cytotoxicity and intellectual property issues, and de-replication.

Compound number	Amastigote EC_{50} mg/ml	Vero EC_{50} mg/ml	Selectivity index (SI)	SI > 48	Selection
HDLSX-171	3.37E-16	> 1.33E+00	> 3.95E+15	Y	Y
HDLSX-106	2.45E-02	1.07E-02	4.38E-01	N	N
HDLSX-67	1.31E-04	6.35E-03	4.84E+01	Y	Y
HDLSX-33	5.22E-04	> 1.33E+00	> 2.55E+03	Y	Y
HDLSX-134	6.66E-04	3.28E-04	4.92E-01	N	N
HDLSX-14	6.84E-04	> 1.33E+00	> 1.94E+03	Y	Y
HDLSX-159	7.94E-04	3.96E-01	4.99E+02	Y	Y
HDLSX-127	9.26E-04	> 1.33E+00	> 1.44E+03	Y	Y
HDLSX-21	2.72E-03	1.34E-01	4.92E+01	Y	Y
HDLSX-208	2.77E-03	> 1.33E+00	> 4.80E+02	Y	N
HDLSX-79	3.26E-03	1.83E+00	5.61E+02	Y	Y
HDLSX-27	3.36E-03	9.97E-03	2.97E+00	N	N
HDLSX-177	3.56E-03	> 1.33E+00	> 3.73E+02	Y	N
HDLSX-84	4.84E-03	1.07E-01	2.21E+01	N	N
HDLSX-23	5.09E-03	2.29E-01	4.50E+01	N	N
HDLSX-179	5.94E-03	1.37E-01	2.31E+01	N	N
HDLSX-130	6.75E-03	> 1.33E+00	> 1.97E+02	Y	N
HDLSX-209	6.86E-03	4.40E-02	6.41E+00	N	N
HDLSX-18	7.15E-03	> 1.33E+00	> 1.86E+02	Y	Y
HDLSX-22	7.42E-03	> 1.33E+00	> 1.79E+02	Y	Y
HDLSX-39	7.55E-03	6.92E-02	9.17E+00	N	N
HDLSX-213	9.05E-03	> 1.33E+00	> 1.47E+02	Y	N
HDLSX-13	9.24E-03	> 1.33E+00	> 1.44E+02	Y	N
HDLSX-72	9.53E-03	1.69E-01	1.77E+01	N	N
HDLSX-126	1.02E-02	> 1.33E+00	> 1.30E+02	Y	N
HDLSX-114	1.03E-02	5.92E-03	5.73E-01	N	N
HDLSX-37	1.18E-02	9.93E-02	8.42E+00	N	N
HDLSX-35	1.37E-02	> 1.33E+00	> 9.71E+01	Y	Y
HDLSX-163	1.44E-02	7.71E-01	5.34E+01	Y	N
HDLSX-180	1.47E-02	> 1.33E+00	> 9.06E+01	Y	N
HDLSX-9	1.47E-02	> 1.33E+00	> 9.03E+01	Y	Y
HDLSX-8	1.48E-02	7.26E-02	4.92E+00	N	N
HDLSX-40	1.61E-02	9.71E-02	6.05E+00	N	N
HDLSX-44	1.74E-02	> 1.33E+00	> 7.63E+01	Y	N
HDLSX-28	1.78E-02	1.32E-01	7.45E+00	N	N
HDLSX-85	1.89E-02	> 1.33E+00	> 7.04E+01	Y	N
HDLSX-211	1.90E-02	> 1.33E+00	> 7.00E+01	Y	N
HDLSX-145	2.06E-02	7.91E-01	3.85E+01	N	N

reported for striatal B (Anke et al., 2002). Notably the striatals have previously demonstrated to be antileishmanial (Inchausti et al., 1997) (Fig. 2). A pure sample of the related compound striatal C was tested and found to have an ED_{50} of < 0.8 μ M, but considerable toxicity to mammalian cells. Other compounds identified at this stage and deprioritised were a glycolipid from HDLSX-18 (HFN67, *Dacryopinax* sp.), which had low potency with an ED_{50} > 100 μ M, and the known metabolite nitidon from HDLSX-67 (HFN528 *Junghuhnia nitida*), which is cytotoxic against other cell lines (Gehrt et al., 1998). The active HDLSX-79 fractions were also dereplicated due to chemical overlap with the HDLSX-22 fractions. This dereplication process left 8 active primary extract fractions to take forward to secondary fractionation and analyses - two from HDLSX-9, and one each from HDLSX-21, 22, 35, 127, 159, 171.

3.3. Secondary fractionation and tertiary screening

Secondary fractions were undertaken of the 8 remaining active primary fractions demonstrating chemical novelty (two from HDLSX-9, and one each from HDLSX-21, 22, 35, 127, 159, 171). These isolated fractions were screened against axenic amastigotes at 1 mg/mL. HDLSX-9, 22, and 127 derived secondary fractions had components demonstrating complete cytotoxic activity against axenic amastigotes, further fractionation of the 5 other primary fractions (including from HDLSX-21 not containing striatal B) did not yield samples with high level activity (Fig. 3). Given that the fractions were screened at equivalent concentrations (1 mg/mL) it is likely that the apparent loss of activity

on further fractionation of these 5 samples was due to a loss of the additive antileishmanial efficacy observed in the initial mixture of compounds. Initial analyses by mass spectrometry indicated the complexity and, in some cases, content of the active fractions. Informed by these analyses, secondary fractions were screened against axenic amastigotes if pure (HDLSX9Fr9 + 10F7 and HDLSX127Fr11Fr9; Fig. 3A and G) or further fractionated (from HDLSX-22; Fig. 3D) before screening. The pure HDLSX-9 (HDLSX9Fr9 + 10F7) secondary fraction had minimal activity against the *L. mexicana* amastigotes (EC_{50} > 100 μ M; data not shown). Furthermore, none of the HDLSX-22 tertiary fractions demonstrated complete cytotoxicity against axenic amastigotes at 1 mg/mL (data not shown). In contrast, the pure HDLSX-127 secondary fraction (HD871-1; HDLSX-127Fr11Fr9 in Fig. 3G) showed good activity (EC_{50} = 4.73 μ M) against the parasite. Furthermore, utilising a previous established assay (Bolt et al., 2016; Eggimann et al., 2015), this compound was tested against infected macrophages and for macrophage cytotoxicity, demonstrating a promising profile with respect to efficacy (EC_{50} = 4.32 μ M) and selectivity (5.51) (Fig. 4).

3.4. Structure elucidation of HD871-1

The ESI-MS spectrum of HD871-1 showed a molecular ion $[MH]^+$ at m/z 263, indicating a molecular weight of 262. High resolution mass measurement of the sodiated molecular ion yielded an m/z value of 285.1095 Da, consistent with a molecular formula of $C_{15}H_{18}O_4$ (the calculated value for $C_{15}H_{18}NaO_4$ is 285.1097 Da). The UV spectrum of HD871-1 showed a maximum absorbance at 226 nm, suggesting the




Figure 1. Screening of primary fractions of the 12 hits against axenic amastigote *L. mexicana* at 1 mg/ml y-axis shows proliferation (%) relative to vehicle (DMSO) treated control. Each selected extract (HDLSX-9, 14, 18, 21, 22, 33, 35, 67, 79, 127, 159, 171) was fractionated into 24 fractions, e.g. HDLSX9.1, 9.3 etc. For clarity, only odd number fractions are labelled on the x-axis.

presence of an α,β -unsaturated carbonyl moiety. The ^1H and ^{13}C NMR data for HD871-1 are summarised in Table 2 and the ^1H , COSY, HSQC, HMBC and NOESY NMR spectra are presented in Supplementary Figures 2–6 respectively. The ^{13}C signals were detected indirectly through the heteronuclear shift correlation HSQC and HMBC spectra and were found to comprise two methyl carbons, four methylene carbons including an olefinic methylene group, four methine carbons including an olefinic methine and five quaternary carbons. Inspection of the ^1H – ^1H COSY spectrum indicated the presence of two fragments comprising C6–C1–C2–C3 and C9–C10–C11–C13 as shown in Fig. 5. HMBC correlations from the methyl proton signal at 1.80 ppm (15-CH_3)

with carbon signals at 143.3, 135.9 and 198.4 ppm (corresponding to positions 2, 3 and 4, respectively) and from the methylene proton signals at 2.55 and 2.44 ppm (5-CH_2) with the carbon signals at 198.4, 36.1 and 31.5 ppm (positions 4, 6 and 1) established the presence of a cyclohexenone ring. HMBC correlations from the olefinic methylene protons at 6.23 and 6.00 ppm to carbons at 36.1, 148.0 and 194.5 ppm (positions 6, 7 and 8) established the connectivity of these with the cyclohexenone moiety. HMBC correlations the methyl proton signal at 1.31 ppm with carbon signals at 33.1, 34.7 and 178.2 ppm were consistent with the presence of a butanolide ring. Although there were no HMBC correlations to connect this with the rest of the molecule, its




Figure 2. A peak (6.5 min) in fraction 14 of HDLSX-21 had a product MH^+ m/z 489.6 and MNH_4^+ m/z 506.6 in the positive ion spectrum (starred in A); and $[M-H]^-$ m/z 487.6 in the negative ion spectrum (starred in B). This corresponded to known antimicrobial striatal B (C).

linkage as shown in Fig. 5 was supported by NOE correlations in the NOESY spectrum between the olefinic methylene protons at 6.23 and 6.00 ppm ($14-CH_2$) and the 9-oxymethine proton at 5.31 ppm. HD871-1 is therefore proposed to be a novel bisabolane sesquiterpene with a high degree of oxygenation and unsaturation.

3.5. Untargeted metabolomics assessment of metabolic perturbation induced by HD871-1

Metabolomics can enable identification of drug targets where these targets represent metabolic enzymes (Vincent and Barrett, 2015). For example, treatment of African trypanosomes with the drug eflornithine

(difluoromethylornithine; DFMO) lead to profound increases in ornithine and loss of putrescine and spermidine, which relates to the drug being an inhibitor of the enzyme ornithine decarboxylase (Vincent et al., 2012). The untargeted metabolomics approach we took does not identify all metabolites within the metabolome, but it does probe many pathways and is able to indicate key areas of perturbed metabolism. The data is reported in Supplementary Table 1. Although multiple peptides and also lipids were noted to change profoundly, we discarded these from further consideration. Peptides often reveal profound changes in kinetoplasts exposed to different drugs as protein turnover is influenced in unpredictable ways. Lipids are not resolved using the hydrophilic chromatography platform used here, hence they tend to




Figure 3. Screening of secondary fractions of the 8 active primary fractions (two from HDLSX-9, and one each from HDLSX-21, 22, 35, 127, 159, 171) against axenic amastigote *L. mexicana* at 1 mg/ml x-axis shows the secondary fractions from the following primary extract fractions: **A** HDLSX9 fractions 9 and 10 (HDLSX9Fr9 + 10); **B** HDLSX9 fraction 13 (HDLSX9Fr13); **C** HDLSX21 fraction 1 (HDLSX21Fr1); **D** HDLSX22 fractions 13 and 14 (HDLSX22Fr13 + 14); **E** HDLSX35 fraction 17 (HDLSX35Fr17); **F** HDLSX159 fractions 12 and 13 (HDLSX159Fr12 + 13); **G** HDLSX127 fraction 11 (HDLSX127Fr11); **H** HDLSX171 fraction 7 (HDLSX171Fr7). y-axis shows proliferation (%) relative to vehicle (DMSO) treated control.

elute at the solvent front during chromatography and suffer poor peak shapes and multitudinous ion suppression effects. Substantial changes did, however, occur to metabolism across many pathways under the conditions used (Fig. 6). However, a clear, individual target could not be identified. Of note was an increase in deoxynucleotide monophosphates and a decrease in deoxynucleotide diphosphates (Fig. 7). These changes point to alterations in nucleotide homeostasis and metabolism, but the impact on cell viability is not certain. Profound decreases in orotate and dihydroorotate also point to an impact on pyrimidine biosynthesis, but pyrimidines themselves are not diminished, presumably due to the parasite's ability to transport and interconvert pyrimidines (Alzahrani et al., 2017). In the absence of the ability to synthesize the purine ring, salvage is essential for *Leishmania* viability (Boitz et al., 2012; Martin et al., 2016). The increase in dAMP and dGMP (Fig. 7) indicated this process was unaffected by HD871-1 treatment. However, dADP was substantially decreased suggesting that further

phosphorylation maybe inhibited (Fig. 7). It was also noteworthy that a mass consistent with trypanothione, the bis(glutathionyl) spermidine adduct that performs key redox roles in *Leishmania* spp and other trypanosomatids, was greatly diminished in treated cells. The peak of this compound ($m/z = 361.6527$ corresponding to the doubly positively charged trypanothione) was poorly resolved by chromatography, hence quantitative comparison is not possible, but treated cells contained profoundly less signal for this mass than untreated cells. In addition to reduced trypanothione, its oxidised disulphide derivative, ($m/z = 361.6441$), was also 3–4 fold less abundant in treated cells, and its thiol precursor glutathione ($m/z = 307.0837$) also diminished in abundance by > 60% in the treated cells. Another poorly resolved peak consistent with the oxidised cysteine derivative, cystine ($m/z = 240.0238$) was identified in treated, but not untreated cells. This accumulated data points to the cells having been exposed to oxidative stresses over the treatment regime.




Figure 3. (continued)

4. Discussion

Given the paucity of safe and effective therapies for CL, and a rising number of cases in an increasing geographic area, the search for novel antileishmanials is as urgent as ever and natural product discovery forms part of this global effort (Charlton et al., 2018; Cockram and Smith, 2018). In this study, using an iterative screening and

fractionation approach, we ‘mined’ the HDLSX library (313 fungal extracts, enriched in small molecule secondary metabolites) for compounds showing activity against *Leishmania mexicana*. A pure secondary fractionation component, HD871-1 (molecular weight of 262), was identified as a potent antileishmanial which demonstrated activity in an infected cell model (Fig. 4). This compound was characterised as a novel bisabolane sesquiterpene with a high degree of oxygenation and




Figure 4. HD871-1 activity against *L. mexicana* axenic amastigotes (red plot line: $EC_{50} = 4.73 \mu M$; 95% Confidence Interval [CI] 3.65–6.12 μM); intramacrophage amastigotes with RAW264.7 cells (black plot line: $EC_{50} = 4.32 \mu M$; 95% CI 3.03–6.15 μM); uninfected RAW264.7 macrophages (blue plot line: $EC_{50} = 23.8 \mu M$; 95% CI 20.9–27.1 μM). From these data the compound was calculated to have a selectivity index of 5.51.

Table 2

1H and ^{13}C NMR assignments for HD871-1 in $CDCl_3$, referenced to internal TMS at 0.00 ppm

Position	HD871-1	
	$\delta_H/ppm, m (J/Hz)$	δ_C/ppm
1	2.51, m; 2.27, ddt (18.0, 10.5, 2.5)	31.5
2	6.73, m	143.3
3		135.9
4		198.4
5	2.55, ddd (16.0, 3.9, 1.4); 2.44, dd (16.0, 12.8)	42.8
6	3.35, m	36.1
7		148.0
8		194.5
9	5.31, dd (9.2, 7.1)	77.0
10	2.62, m; 2.02, m	33.1
11	2.75, m	34.7
12		178.2
13	1.31, d (7.1)	15.5
14	6.23, s; 6.00, s	127.0
15	1.80, s	16.1

unsaturation (Fig. 5, Table 2). HD871-1 has structural similarities to cheimonophyllons A-E, bisabolane sesquiterpenes isolated from fermentations of the basidiomycete *Cheimonophyllum candidissimum*, which have been shown to demonstrate nematicidal properties (Stadler and Anke, 1994). Taken together, these studies indicate that this class of compounds could represent a new class of broad-spectrum of antiparasitics.

However, to best take forward and develop any antileishmanial/antiparasitic the identification of the mode of action is key. To begin deconvolution of the target of HD871-1, in this study metabolomics was used to identify changes to the metabolic network of *L. mexicana* amastigotes exposed to HD871-1. Using a 36 h timepoint and compound dose 2-fold higher than the EC_{50} , a number of clear changes to metabolism occurred (Supplementary Table 1), although a single clear hit pointing to a specific enzyme targeted by the drug was not apparent (as had been found, for example, using eflornithine against *T. brucei*, Vincent et al., 2012). Changes in the deoxynucleotide pool indicated possible changes in nucleotide homeostasis and metabolism, although whether this is a cause of cell death, or a secondary effect due to other changes is not clear. Loss of the chief redox reactive thiol trypanothione and accumulation of cystine pointed to oxidative stress being induced by HD871-1. The presence of two α,β -unsaturated ketone moieties in




Figure 5. Structure of HD871-1 (A); key COSY, HMBC and NOE correlations (B).




Figure 6. Principle Component Analysis (PCA) plot showing the global differences between treated and untreated cells. Five replicates of the measured metabolites from untreated (blue dots) and treated with HD871 (red dots). The green dots show pooled samples from both types and indicate good reproducibility across the machine run. PC1 and 2 = Principle Components.

the structure of HD871-1 with the potential to act as Michael acceptors suggests a likely reactive nature towards appropriate nucleophiles such as trypanothione and glutathione. Since both reduced and oxidised trypanothione were diminished, as was glutathione, a possible role in drug binding prior to efflux from the cell, as occurs in the parasite response to antimony (Wyllie et al., 2004), would be worthy of future investigation.




Figure 7. Effect on nucleotide metabolism in *Leishmania mexicana* axenic amastigotes treated with HD871-1, 10 μ M for 36 h at 32 °C. Compared with untreated samples (DMSO, U), levels of dAMP, dTMP, dCMP and dGMP all climbed significantly during the course of treatment while the dinucleotides dADP and dTDP diminished (dGDP and dCDP were not identified). Orotate and dihydroorotate were both significantly diminished by treatment. y-axis is arbitrary units (AU).

5. Conclusions

Using an iterative process of screening and fractionation a novel bisabolane sesquiterpene antileishmanial was identified from a fungal extract library. Metabolomic analyses indicated that the compound induced oxidative stress in the parasite. Further analyses are required to fully define the mode of action, however the process described sets a precedent for the discovery of much needed novel antileishmanials.

Declarations of interest

None.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.ijpddr.2019.05.003>.

Acknowledgements and Funding

This project was supported by the Biotechnology and Biological Sciences Research Council through a Sparking Impact Award (Durham University) and a Proof of Concept grant (NPRONET, the natural products and bioengineering network). The research leading to these results has, in part, received funding from UK Research and Innovation via the Global Challenges Research Fund under grant agreement 'A Global Network for Neglected Tropical Diseases' grant number MR/P027989/1.

References

Alzahrani, K.J.H., Ali, J.A.M., Eze, A.A., Looi, W.L., Tagoe, D.N.A., Creek, D.J., Barrett, Michael P., de Koning, H.P., 2017. Functional and genetic evidence that nucleoside transport is highly conserved in *Leishmania* species: implications for pyrimidine-based chemotherapy. *Int J Parasitol Drugs Drug Resist* 7.

Anke, T., Rabe, U., Schu, P., Eizenhofer, T., Schrage, M., Steglich, W., 2002. Studies on the biosynthesis of striatal-type diterpenoids and the biological activity of herical. *Z Naturforsch* 57c, 263–271.

Aponte, J.C., Castillo, D., Estevez, Y., Gonzalez, G., Arevalo, J., Hammond, G.B., Sauvain, M., 2010. In vitro and in vivo anti-Leishmania activity of polysubstituted synthetic chalcones. *Bioorg. Med. Chem. Lett* 20, 100–103.

Arruda, D.C., D'Alexandri, F.L., Katzin, A.M., Uliana, S.R., 2005. Antileishmanial activity of the terpene nerolidol. *Antimicrob. Agents Chemother.* 49, 1679–1687.

Bates, P.A., 1994. Complete developmental cycle of *Leishmania mexicana* in axenic culture. *Parasitology* 108 (Pt 1), 1–9.

Boeck, P., Bandeira Falcao, C.A., Leal, P.C., Yunes, R.A., Filho, V.C., Torres-Santos, E.C., Rossi-Bergmann, B., 2006. Synthesis of chalcone analogues with increased antileishmanial activity. *Bioorg. Med. Chem.* 14, 1538–1545.

Boitz, J.M., Ullman, B., Jardim, A., Carter, N.S., 2012. Purine salvage in *Leishmania*: complex or simple by design? *Trends Parasitol.* 28, 345–352.

Bolt, H.L., Eggimann, G.A., Denny, P.W., Cobb, S.L., 2016. Enlarging the chemical space of anti-leishmanials: a structure-activity relationship study of peptoids against *Leishmania mexicana*, a causative agent of cutaneous leishmaniasis. *Med.Chem.Comm* 7, 799–805.

Bray, P.G., Barrett, M.P., Ward, S.A., de Koning, H.P., 2003. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. *Trends Parasitol.* 19, 232–239.

Burza, S., Croft, S.L., Boelaert, M., 2018. Leishmaniasis. *Lancet* 392, 951–970.

Chadbourne, F.L., Raleigh, C., Ali, H.Z., Denny, P.W., Cobb, S.L., 2011. Studies on the antileishmanial properties of the antimicrobial peptides temporin A, B and 1Sa. *J. Pept. Sci.* 17, 751–755.

Chappuis, F., Sundar, S., Hailu, A., Ghalib, H., Rijal, S., Peeling, R.W., Alvar, J., Boelaert, M., 2007. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? *Nat. Rev. Microbiol.* 5, 873–882.

Charlton, R.L., Rossi-Bergmann, B., Denny, P.W., Steel, P.G., 2018. Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art. *Parasitology* 145, 219–236.

Chen, M., Christensen, S.B., Theander, T.G., Kharazmi, A., 1994. Antileishmanial activity of licochalcone A in mice infected with *Leishmania major* and in hamsters infected with *Leishmania donovani*. *Antimicrob. Agents Chemother.* 38, 1339–1344.

Cockram, P.E., Smith, T.K., 2018. Active natural product scaffolds against trypanosomatid parasites: a review. *J. Nat. Prod.* 81, 2138–2154.

Creek, D.J., Jankevics, A., Burgess, K.E., Breitling, R., Barrett, M.P., 2012. IDEOM: an Excel interface for analysis of LC-MS-based metabolomics data. *Bioinformatics* 28, 1048–1049.

Creek, D.J., Jankevics, A., Rainer, B., Watson, D.G., Barrett, M.P., Burgess, K.E., 2011. Toward global metabolomics analysis with hydrophilic interaction liquid chromatography-mass spectrometry: improved metabolite identification by retention time prediction. *Anal. Chem.* 83, 8703–8710.

Croft, S.L., Coombs, G.H., 2003. Leishmaniasis—current chemotherapy and recent advances in the search for novel drugs. *Trends Parasitol.* 19, 502–508.

Croft, S.L., Sundar, S., Fairlamb, A.H., 2006. Drug resistance in leishmaniasis. *Clin. Microbiol. Rev.* 19, 111–126.

da Silva, E.R., Maquiaveli Cdo, C., Magalhaes, P.P., 2012. The leishmanicidal flavonols quercetin and quercitrin target *Leishmania (Leishmania) amazonensis* arginase. *Exp. Parasitol.* 130, 183–188.

de Mello, T.F., Bitencourt, H.R., Pedrosa, R.B., Aristides, S.M., Lonardon, M.V., Silveira, T.G., 2014. Leishmanicidal activity of synthetic chalcones in *Leishmania (Viannia) braziliensis*. *Exp. Parasitol.* 136, 27–34.

Demicheli, C., Ochoa, R., da Silva, J.B., Falcao, C.A., Rossi-Bergmann, B., de Melo, A.L., Sinisterra, R.D., Frezard, F., 2004. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis. *Antimicrob. Agents Chemother.* 48, 100–103.

Di Giorgio, C., Faraut-Gambarelli, F., Imbert, A., Minodier, P., Gasquet, M., Dumon, H., 1999. Flow cytometric assessment of amphotericin B susceptibility in *Leishmania infantum* isolates from patients with visceral leishmaniasis. *J. Antimicrob. Chemother.* 44, 71–76.

do Socorro, S.R.M.S., Mendonca-Filho, R.R., Bizzo, H.R., de Almeida Rodrigues, I., Soares, R.M., Souto-Pradon, T., Alviano, C.S., Lopes, A.H., 2003. Antileishmanial activity of a linalool-rich essential oil from *Croton cajucara*. *Antimicrob. Agents Chemother.* 47,

- 1895–1901.
- Dutcher, J.D., 1968. The discovery and development of amphotericin B. *Dis. Chest* 54 (Suppl. 1), 296–298.
- Eggimann, G.A., Bolt, H.L., Denny, P.W., Cobb, S.L., 2015. Investigating the anti-leishmanial effects of linear peptoids. *ChemMedChem* 10, 233–237.
- Gehrt, A., Erkel, G., Anke, T., Sterner, O., 1998. Nitidon, a new bioactive metabolite from the basidiomycete *Junghuhnia nitida* (Pers. Fr.) Ryv. *Z. Naturforsch. C* 53, 89–92.
- Inchausti, A., Yaluff, G., deArias, A.R., Torres, S., Ferreira, M.E., Nakayama, H., Schinini, A., Lorenzen, K., Anke, T., Fournet, A., 1997. Leishmanicidal and trypanocidal activity of extracts and secondary metabolites from basidiomycetes. *Phytother Res.* 11, 193–197.
- Kedzierski, L., Sakthianandeswaren, A., Curtis, J.M., Andrews, P.C., Junk, P.C., Kedzierska, K., 2009. Leishmaniasis: current treatment and prospects for new drugs and vaccines. *Curr. Med. Chem.* 16, 599–614.
- Khare, S., Nagle, A.S., Biggart, A., Lai, Y.H., Liang, F., Davis, L.C., Barnes, S.W., Mathison, C.J., Myburgh, E., Gao, M.Y., et al., 2016. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. *Nature* 537, 229–233.
- Kováčová, J., Pountain, A.W., Wildridge, D., Weidt, S., Bringaud, F., Burchmore, R.J.S., Achcar, F., Barrett, M.P., 2018. Deletion of transketolase triggers a stringent metabolic response in promastigotes and loss of virulence in amastigotes of *Leishmania mexicana*. *PLoS Pathog.* 14, e1006953.
- Martin, J.L., Yates, P.A., Boitz, J.M., Koop, D.R., Fulwiler, A.L., Cassera, M.B., Ullman, B., Carter, N.S., 2016. A role for adenine nucleotides in the sensing mechanism to purine starvation in *Leishmania donovani*. *Mol. Microbiol.* 101, 299–313.
- Mishra, B.B., Singh, R.K., Srivastava, A., Tripathi, V.J., Tiwari, V.K., 2009. Fighting against Leishmaniasis: search of alkaloids as future true potential anti-Leishmanial agents. *Mini Rev. Med. Chem.* 9, 107–123.
- Mittra, B., Saha, A., Chowdhury, A.R., Pal, C., Mandal, S., Mukhopadhyay, S., Bandyopadhyay, S., Majumder, H.K., 2000. Luteolin, an abundant dietary component is a potent anti-leishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis. *Mol. Med.* 6, 527–541.
- Norcliffe, J.L., Mina, J.G., Alvarez, E., Cantizani, J., de Dios-Anton, F., Colmenarejo, G., Valle, S.G., Marco, M., Fiandor, J.M., Martin, J.J., et al., 2018. Identifying inhibitors of the *Leishmania* inositol phosphorylceramide synthase with antiprotozoal activity using a yeast-based assay and ultra-high throughput screening platform. *Sci. Rep.* 8, 3938.
- Pena, I., Pilar Manzano, M., Cantizani, J., Kessler, A., Alonso-Padilla, J., Bardera, A.I., Alvarez, E., Colmenarejo, G., Cutillo, I., Roquero, I., et al., 2015. New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource. *Sci. Rep.* 5, 8771.
- Reithinger, R., Dujardin, J.C., Louzir, H., Pirmez, C., Alexander, B., Brooker, S., 2007. Cutaneous leishmaniasis. *Lancet Infect. Dis.* 7, 581–596.
- Scheltema, R.A., Jankevics, A., Jansen, R.C., Swertz, M.A., Breitling, R., 2011. PeakML/mzMatch: a file format, Java library, R library, and tool-chain for mass spectrometry data analysis. *Anal. Chem.* 83, 2786–2793.
- Stadler, M., Anke, H., 1994. New nematocidal and antimicrobial compounds from the basidiomycete *Cheimonophyllum candidissimum* (Berk & Curt.) sing. I. Producing organism, fermentation, isolation, and biological activities. *J. Antibiot. (Tokyo)* 47, 1284–1289.
- Stuart, K., Brun, R., Croft, S., Fairlamb, A., Gurtler, R.E., McKerrow, J., Reed, S., Tarleton, R., 2008. Kinetoplastids: related protozoan pathogens, different diseases. *J. Clin. Invest.* 118, 1301–1310.
- Sumner, L.W., Amberg, A., Barrett, D., Beale, M.H., Beger, R., Daykin, C.A., Fan, T.W., Fiehn, O., Goodacre, R., Griffin, J.L., et al., 2007. Proposed minimum reporting standards for chemical analysis chemical analysis working group (CAWG) metabolomics standards initiative (MSI). *Metabolomics* 3, 211–221.
- Thakur, C.P., Singh, R.K., Hassan, S.M., Kumar, R., Narain, S., Kumar, A., 1999. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. *Trans. R. Soc. Trop. Med. Hyg.* 93, 319–323.
- Vincent, I.M., Barrett, M.P., 2015. Metabolomic-based strategies for anti-parasite drug discovery. *J. Biomol. Screen* 20, 44–55.
- Vincent, I.M., Creek, D.J., Burgess, K., Woods, D.J., Burchmore, R.J., Barrett, M.P., 2012. Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against *Trypanosoma brucei*. *PLoS NTD* 6, e1618.
- Wyllie, S., Cunningham, M.L., Fairlamb, A.H., 2004. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen *Leishmania donovani*. *J. Biol. Chem.* 279, 39925–39932.